Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Pharmacoeconomics
|
June 20, 2016
Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
Jamie Elvidge, Ash Bullement, Anthony J Hatswell
Journal of Medical Economics
|
July 17, 2020
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
Holly Cranmer, Gemma E Shields, Ash Bullement
Applied Health Economics and Health Policy
|
February 28, 2023
An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology
Holly L Cranmer, Gemma E Shields, Ash Bullement
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2019
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement, Nicholas R Latimer, Helen Bell Gorrod
Applied Health Economics and Health Policy
|
September 6, 2019
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
Ash Bullement, Holly L Cranmer, Gemma E Shields
Journal of Medical Economics
|
May 20, 2025
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs
Audrey Petitjean, Huiyu Shang, Ash Bullement, et al.
Applied Health Economics and Health Policy
|
December 14, 2020
What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
Anthony J Hatswell, Ash Bullement, Michael Schlichting, et al.
Clinical Colorectal Cancer
|
November 8, 2017
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Ash Bullement, Stuart Underhill, Ronan Fougeray, et al.
Pharmacoeconomics
|
December 6, 2021
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time
Gemma E Shields, Becky Pennington, Ash Bullement, et al.
Pharmacoeconomics - Open
|
July 16, 2021
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
Ash Bullement, Emma S Knowles, Pronabesh DasMahapatra, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Pharmacoeconomics
|
June 20, 2016
Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
Jamie Elvidge, Ash Bullement, Anthony J Hatswell
Journal of Medical Economics
|
July 17, 2020
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
Holly Cranmer, Gemma E Shields, Ash Bullement
Applied Health Economics and Health Policy
|
February 28, 2023
An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology
Holly L Cranmer, Gemma E Shields, Ash Bullement
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2019
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement, Nicholas R Latimer, Helen Bell Gorrod
Applied Health Economics and Health Policy
|
September 6, 2019
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
Ash Bullement, Holly L Cranmer, Gemma E Shields
Journal of Medical Economics
|
May 20, 2025
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs
Audrey Petitjean, Huiyu Shang, Ash Bullement, et al.
Applied Health Economics and Health Policy
|
December 14, 2020
What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
Anthony J Hatswell, Ash Bullement, Michael Schlichting, et al.
Clinical Colorectal Cancer
|
November 8, 2017
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Ash Bullement, Stuart Underhill, Ronan Fougeray, et al.
Pharmacoeconomics
|
December 6, 2021
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time
Gemma E Shields, Becky Pennington, Ash Bullement, et al.
Pharmacoeconomics - Open
|
July 16, 2021
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
Ash Bullement, Emma S Knowles, Pronabesh DasMahapatra, et al.
Page
of 3